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Abstract: Four different hybrid compounds have been efficiently 
synthetized by conjugation of deacetylthiocolchicine with pironetin 
inspired derivatives. The modest bioactivity and the apparent 
absence of interaction with α-tubulin is explained by a posteriori in 
silico investigation that suggested a relevant distance between the 
thiocolchicine binding site and the proper pocket on the α-tubulin. 
The modest activity on resistant cells suggested that the lipophilic 
nature of the used linker renders the obtained compounds better 
substrates for p-Gp efflux pumps. The study better clarifies the 
design of hetero tubulin/microtubules-targeting bivalent compounds. 
Keywords: bivalent binder, microtubules, pironetin, tubulin binder, 
thiocolchicine,  
Introduction 
Microtubules (MTs) are highly dynamic structures, diffused in 
eukaryotic cells, as well as in some bacteria.[1] They are 
fundamental components of the cytoskeleton and they play 
important roles in several essential cellular processes, such as 
cell division, locomotion, intracellular transport and cell shape 
definition. MTs are originated from the head-to-tail arrangement 
of α,β-tubulin heterodimers, leading to the formation of 
cylindrical assemblies. In physiological conditions, MTs are 
characterized by alternating phases of growth and shrinkage, a 
behaviour known as “dynamic instability”. This dynamism is 
essential for MTs correct functionality, in particular for the 
formation of the mitotic spindle during the mitosis process.[2] The 
perturbation of this dynamic behaviour can result in deleterious 
effects for the cells, halting the cell replication and inducing 
cellular apoptosis. Therefore, MTs represent very suitable drug 
target, for anticancer therapy and also for neurodegenerative 
diseases treatment, as recently emerged. In fact, MTs dynamic 
instability is essential in many neuronal activities, which are 
regulated by tubulin post translational modifications.[3] 
Depending on the mode of action, MT-targeting agents can be 
divided into two different families: MT-stabilizing agents and MT-
destabilizing agents. In the last decade, both these classes have 
been successfully applied in the treatment of several cancer 
types,[4] and the search of new cytotoxic or neuroprotective 
agents is still of primary interest. Thus, our interest in the 
obtainment of new molecules able to target tubulin and MTs, 
prompted us to plan the synthesis of new tubulin/microtubules-
targeting bivalent compounds. Bifunctional drugs, bearing 
chemical entities that are able to bind to separate sites of the 
protein, recently attracted the attention of the scientific 
community, thanks to their possible great pharmacological 
potential. The idea of conjugating different MTs binders into 
bivalent entities led to the obtainment of novel antimitotic agents, 
including taxoid-colchicine,[5] vinca alkaloids-taxoid hybrids,[6] 
colchicine–tubulizine,[7] colchicine-pironetin,[8] podophyllotoxin-
thiocolchicine and hybrids merging histone deacetylase 
inhibitors with different tubulin binders.[9], [10] On one hand the 
use of too short or rigid linkers prevents the interaction with the 
desired binding site and leads to steric clashes. On the other 
hand, the use of a too long and flexible linker may lead to 
solubility and cell internalization problems.[11] As the linker 
seems to play a critical role tuning the bioactivity of these class 
of molecules, we planned the synthesis of new bivalent 
compounds, constituted by a well known β-tubulin binder 
(thiocolchicine) and a pironetin inspired compound (hybrid 1, 
Figure 1) connected by linkers of different types and length, to 
investigate how their properties affect the binding capability. 
Results and Discussion 
For the first explorative studies a 10-atom all-carbon chain and a 
24-atom pseudo-peptidic chain were taken into account. As 
active units, we choose thiocolchicine and hybrid compound 1 
as models of β- and possible α-binder, respectively (Figure 1). 
Compounds 1 were recently designed in our laboratory, as the 
merging of two natural compounds, pironetin and dumetorine.[12]  
Pironetin is an α-tubulin binder, characterized by a δ-
unsaturated lacton, which serves as Michael acceptor for the 
[a] Dr. E. Bonandi, Dr. F. Foschi, Dr. F. Dapiaggi, Prof. M. Sironi, Dr. S. 
Pieraccini, Prof. D. Passarella  
Dipartimento di Chimica  
Università degli Studi di Milano  
 via Golgi 19, 20133 Milano, Italy 
 E-mail: daniele.passarella@unimi.it 
[b] Dr. M. S. Christodoulou 
Dipartimento di Scienze Farmaceutiche 
Università degli Studi di Milano  
 via Golgi 19, 20133 Milano, Italy 
[c] Dr. F. de Asís Balaguer, Dr. J. F. Díaz 
Chemical and Physical Biology 
Centro de Investigaciones Biológicas, Consejo Superior de 
Investigaciones Cientificas CIB–CSIC 
 Madrid 28040, Spain 
[d] Dr. N. Zidar 
Faculty of Pharmacy 
University of Ljubljana 
 Askerceva cesta 7, 1000, Ljubljana, Slovenia 
  
Supporting information for this article is available on the WWW 
under http://dx.doi.org/10.1002/cplu.201xxxxx 






Cys316 residue inside α-tubulin binding site.[13] It is noteworthy 
that while several β-tubulin binders are currently available, only 
few molecules are known to bind α-tubulin.  
The modification of pironetin structure, introducing the piperidine 
ring typical of dumetorine, resulted in the obtainment of an 
anchor point exploitable for the synthesis of bivalent compounds. 
   
Figure 1. General scheme for the assembly of the conjugate compounds 
and representation of the employed specific components. 
We took into consideration three of the eight prepared 
stereoisomers,[12] in particular 1a-c, for the synthesis of the new 
conjugate compounds on the base of their efficacy in giving 
stable and pure compounds. First, N-deacetyl-10-thiocolchicine 
2, deriving by acidic hydrolysis of thiocolchicine,[14] was 
converted into compound 3, exploiting a condensation with 
sebacic acid. A strict control over the amount of sebacic acid 
avoided the undesired reaction on both the carboxylic moieties. 
Reaction of 3 with compound 1a in the presence of HATU and 
DIPEA, afforded compound 4, characterized by a linker of 10 
carbon atoms (Scheme 1).  
 
Scheme 1. Reagents and conditions: a) HCl 2M, MeOH, 85°C, 3 days; b) 
sebacic acid, HATU, DIPEA, CH2Cl2, rt, 3h; c) 1a, HATU, DIPEA, CH2Cl2, 
rt, 4 h.  
The condensation reaction of compound 3 with 1b and 1c gave 
unexpectedly complex mixture of compounds probably due to 
the intrinsic instability of the desired compounds. The synthesis 
of conjugate compounds bearing a longer pseudo-peptidic linker 
was considered (Scheme 2). To this extent, the 10 carbon atoms 
chain of compound 3 was furtherly elongated, through the 
introduction of the tert-butyl 2-aminoethylcarbamate fragment 5, 
obtained according to reported procedure.[15] The cleavage of 
the Boc protecting group, upon treatment with TFA led to 
compound 7. The obtained free amino group, was exploited for a 
further reaction with sebacic acid. Under these conditions, the 
thiocolchicine derivative 8 was obtained as major product. Final 
compounds 9a-c were accessed by condensation reaction 
between 8 and the proper stereoisomer 1.  
 
Scheme 2. Reagents and conditions: a) 5, HATU, DIPEA, CH2Cl2, rt, 3h; 
b) TFA, CH2Cl2, 0°C to rt, 1h; c) sebacic acid, HATU, DIPEA, CH2Cl2, rt, 
3h; d) 1a-c, HATU, DIPEA, CH2Cl2, rt, 3h. 
Biological data. We submitted compounds 4 and 9a-c to 
preliminary biological tests, aimed at the elucidation of their 
activity as tubulin/microtubules targeting compounds. Firstly, 
they were tested on wild -type and resistant ovarian cancer cells 
lines (A2780 and A2780AD respectively). Cytotoxicity data 
(reported in Table 1) seem to suggest that our compounds do 
not interact through the pironetin-like unit. In fact, if this was the 
case, they would have accumulated inside the cells, avoiding the 
P-glycoprotein resistance like other MTs covalent binders 
usually do.[16] Compound 4 is almost as toxic as N-deacetyl-10-
thiocolchicine 2 in non-resistant cells but 100 times less toxic in 
resistant cells; compounds 9a-c displayed even less toxicity, and 
also in this case the trend is more marked on resistant cells. 






These results prompted us to think that our bivalent compounds 
interact with tubulin exploiting only the thiocolchicine, justifying in 
this way the partially retained bioactivity. However, the 
hydrophobic linker seems to disturb the interaction of pironetin 
with the target, as well as render our compounds better 
substrates for P-glycoprotein, as emerged considering that the 
activity decreases with the length of the linker. Furthermore, to 
confirm that the retained antiproliferative activity of the obtained 
compounds was actually related to their capacity to destabilize 




Podophyllotoxin and N-deacetyl-10-thiocolchicine were also 
tested, for comparative purposes. The results of the tubulin 
polymerization assay are reported in Figure 2. As can be 
deducted from the graphic, all the tested compounds show a 
strong destabilizing effect, indicating that the toxicity observed is 
exerted through inhibition of tubulin assembly. This is coherent 
with the assumption that the partial activity of our compounds 
depends from the interaction of the thiocolchicine moiety with 
tubulin. These results highlight a slightly difference in activity 
between compound 4 and compounds 9a-c, differing in linker 
length. In particular, the plain inability of the obtained hybrid 
compounds to exploit the dual interaction with 
tubulin/microtubules can be inferred from the data. These 
observations prompted us to investigate the binding mode of 
these compounds through molecular modelling studies. 
 
 
Figure 2. Time course of 25 M tubulin polymerization at 37 ºC 
measured by 350 nm turbidimetry in the presence of DMSO vehicle 
(control) or 27.5 M of ligand. The assay was performed as triplicate and 
the graph represent the mean of the three experiments. 
Molecular dynamics simulations. Molecular Dynamics (MD) 
simulations are a useful tool to assess the conformational 
stability of a ligand within the binding site. MD simulations were 
performed on compounds 4, 9a, colchicine and N-deacetyl-10-
thiocolchicine in complex with a tubulin α-β dimer. We chose the 
PDB 4O2B[17] (tubulin-colchicine complex) as the starting 
structure for MD simulations. This choice is justified by a higher 
resolution compared to any tubulin-thiocolchicine solved 
structure.[11] Moreover colchicine and thiocolchicine are very 
similar molecules and the conformation of the residues forming 
the binding site is largely superimposable. The experimental 
results suggested that ligands interact with tubulin through the 
N-deacetyl-10-thiocolchicine moiety. Accordingly, in the MD 
starting structures the N-deacetyl-10-thiocolchicine nucleus of 
each ligand was placed into the colchicine binding site while the 
pironetin moiety was placed between α-β subunits (see 
Supporting information, Figure S1). A 50ns MD simulation for 
each complex was performed and subsequently the root mean 
square deviation (RMSD) were computed with respect to the 
staring structure for each ligand after least square fit to protein 
Cα (Figure 3). From these data it resulted that the longer is the 
linker, the greater is the displacement of the ligands within the 
binding site.  
On the other hand, colchicine and N-deacetyl-10-thiocolchicine 
show a low and stationary RMSD trend. In Figure S2 
(Supporting information), the superimposition of the final 
structure of the MD of compound 4 with the crystallographic 
structure of tubulin-thiocolchinine complex can be compared 
(PDB ID: 5LP6). It is possible to infer that the presence of the 
linker has a displacing effect on the thiocolchinine nucleus, 
which can lead to a partial loss of its key hydrophobic 
interactions with the β-monomer. 
Table 1. Cytotoxicity data.  
Compound IC50 [nM]
[a] R/S[b] 
 A2780 A2780AD  
4 11.8±1 4300±600 364 
9a 252±7 20500±500 81 
9b 205±15 19000±6000 93 
9c 196±0.2 46000±1500 235 
Colchicine 13.6±2 663±23 49 
N-deacetyl-10-
thiocolchicine 
7.8±1 30.9±0.6 4 
Paclitaxel 0.4±0.08 1400±200 3500 
Podophyllotoxin 8±1 10.1±0.7 1.2 
[a] IC50 values determined in the parental ovarian carcinoma A2780 line 
and the MDR P-glycoprotein-overexpressing ovarian carcinoma 
A2780/AD10. IC50 values in nm were determined after two days’ 
exposure to drugs using the MTT cell proliferation assay. Data are the 
mean ± SE of at least four independent experiments. [b] Ratio of 
IC50(resistant cell line)/IC50(parental cell line). Values are the calculated 
relative resistance of each mutant cell line obtained by dividing the IC50 
value of the resistant line by the IC50 value of the parental line, A2780. 







Figure 3. RMSD plot for the ligands. Colchicine and N-deacetyl-10-
thiocolchicine show a low and stationary value of RMSD while the linker 
of compounds 4 and 9a has a negative effect on the conformational 
stability of the molecules within the binding site. 
Moreover, the root mean square fluctuations (RMSF) for ligands 
with heavy atoms was considered (Figure 4). Once again, it is 
evident that the presence of a long linker (compound 9a, red 
line) leads to a higher mobility of the thiocolchicine moiety. This 
effect is less pronounced in the case of compound 4, which has 
a shorter linker. Colchicine and N-deacetyl-10-thiocolchicine 
show the lowest RMSF values, suggesting that any of these 
linkers has a negative impact on the ligands binding mode. 
 
Figure 4. RMSF plot for the ligands. The fluctuations are higher for 
compound 9a, which has the longest linker. 
Conclusions 
In conclusion, four different conjugate compounds have been 
efficiently synthetized by linking thiocolchicine nucleus with 
pironetin inspired derivatives. One of them presents 10 atom 
linker and three of them present 24 atom (C10-N-C2-N-C10) linker. 
The detected reduced bioactivity and the apparent absence of 
interaction by the α-tubulin binder prompted us to employ an in 
silico approach to evaluate the binding mode of the compounds. 
The MD results suggest that a longer linker has a displacing 
effect on the thiocolchinine nucleus, probably resulting in a loss 
of activity. The observed diminished activity on resistant cells 
whispers that the lipophilic nature of the linker renders the 
described compounds, better substrates for p-Gp efflux pumps. 
The design and the synthesis of conjugate tubulin/microtubules 
targeting compounds by linking one alfa- with one beta-binder is 
feasible and handle. In contrast this study demonstrates that the 
aim to improve tubulin/microtubules targeting by an bivalent 
binder sounds unlikely due to the required dimension and the 
tricky relevance of the linker.  
Experimental Section 
Experimental details (chemistry, molecular dynamics simulations and 
Biology) are given in the Supporting Information. 
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